Pj Anand

PJ is the founder of Alcyone Therapeutics and its predecessor Alcyone Lifesciences, and serves as the CEO. PJ sets the vision for the company including corporate strategy, research & development, business devlopment and commercialization.

PJ has 25+ years of experience in the life science industry with a lab to clinic translational track-record of next-generation technologies for use in treatment of end-stage kidney disease, peripheral vascular disease, orthopedic and CNS disorders including brain cancer and diagnostics. He is a recognized expert in translating academic research into clinical value proposition, and in the area of convergence of drugs and devices. He also has over 100 families of patents and patent applications and several scientific publications to his credit. PJ is also the founder of Anuncia, Inc., a company focused on treatment and management of cerebrospinal fluid dysfunction including hydrocephalus and the co-founder and Chairman of Arthromeda, Inc., a company focused on developing an A.I. based patient-specific navigation platform for orthopedic applications. Before founding Alcyone Lifesciences and Arthromeda, PJ Anand was a founding executive member of WMR Biomedical (now Arsenal Medical & Lyra Therapeutics) where he was responsible for key strategic funding transactions.

Early in his career, PJ served as Vice President & General Manager of Spire Biomedical, Inc., a division of Spire Corporation, where he was responsible for developing a convergence product for the treatment of ESRD that resulted M&A transaction.